Assessing the quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) in immuno-oncology (I/O): An application to nivolumab vs. everolimus in previously treated advanced renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Shah, R.; Botteman, M.; Solem, C.; Luo, L.; Doan, J.; Cella, D.; Motzer, R. J. |
| Abstract Title: | Assessing the quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) in immuno-oncology (I/O): An application to nivolumab vs. everolimus in previously treated advanced renal cell carcinoma (aRCC) |
| Meeting Title: | 2018 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2018 Feb 8-10 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-02-20 |
| Language: | English |
| ACCESSION: | WOS:000436179500663 |
| DOI: | 10.1200/JCO.2018.36.6_suppl.669 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 669 -- Source: Wos |
